INTRODUCTION: HIV seropositivity is considered a risk factor for complications in hepatitis A virus (HAV) infection. HAV vaccination schedules are widely implemented in HIV-infected patients, but the immune response remains impaired. METHODS: We analysed the response to vaccination (antiHAV titres ≥20IU/l) in 282 HIV-infected patients included in a standard (1440 Elisa Units (EU) at 0, 6 months) or rapidly accelerated schedule (720 EU at 0, 7, 21 days and 6 months) between 1997 and 2009. Factors associated with the response to vaccination were analysed using logistic regression. RESULTS: The overall response rate was 73.4%. Male sex (OR: 0.16, 95% CI 0.05-0.51) and hepatitis C virus co-infection (OR: 0.30, 95% CI 0.14-0.74) were associated with a lower probability of response. Protective antibody response was associated with a higher CD4/CD8 ratio (OR: 3.69, 95% CI 1.3-10.5) and having received two doses of standard schedule (compared with patients receiving only one dose of the same schedule) (OR: 2.51, 95% CI 1.22-5.15). Three doses of the rapidly accelerated schedule were not more effective than a single dose of 1440 EU (OR: 1.32, 95% CI 0.48-3.63). CONCLUSION: The low responses observed in patients receiving a single dose suggest the need to emphasize adhesion to vaccination protocols to avoid failure. The CD4/CD8 ratio may be considered as an immune status marker which could help to better choose the moment of vaccination. Our findings underscore the importance of identifying strategies that optimize the timing and effectiveness of hepatitis A vaccination in HIV-infected patients and of the need for further studies on individual factors such as sex and hepatitis C co-infection that may affect the response to vaccination. Likewise, the sub-optimal effectiveness of three doses of 720 EU in the rapidly accelerated schedule, if confirmed in future studies, might lead to a revision of the current schedule recommended for HIV-infected travellers.
INTRODUCTION: HIV seropositivity is considered a risk factor for complications in hepatitis A virus (HAV) infection. HAV vaccination schedules are widely implemented in HIV-infectedpatients, but the immune response remains impaired. METHODS: We analysed the response to vaccination (antiHAV titres ≥20IU/l) in 282 HIV-infectedpatients included in a standard (1440 Elisa Units (EU) at 0, 6 months) or rapidly accelerated schedule (720 EU at 0, 7, 21 days and 6 months) between 1997 and 2009. Factors associated with the response to vaccination were analysed using logistic regression. RESULTS: The overall response rate was 73.4%. Male sex (OR: 0.16, 95% CI 0.05-0.51) and hepatitis C virus co-infection (OR: 0.30, 95% CI 0.14-0.74) were associated with a lower probability of response. Protective antibody response was associated with a higher CD4/CD8 ratio (OR: 3.69, 95% CI 1.3-10.5) and having received two doses of standard schedule (compared with patients receiving only one dose of the same schedule) (OR: 2.51, 95% CI 1.22-5.15). Three doses of the rapidly accelerated schedule were not more effective than a single dose of 1440 EU (OR: 1.32, 95% CI 0.48-3.63). CONCLUSION: The low responses observed in patients receiving a single dose suggest the need to emphasize adhesion to vaccination protocols to avoid failure. The CD4/CD8 ratio may be considered as an immune status marker which could help to better choose the moment of vaccination. Our findings underscore the importance of identifying strategies that optimize the timing and effectiveness of hepatitis A vaccination in HIV-infectedpatients and of the need for further studies on individual factors such as sex and hepatitis C co-infection that may affect the response to vaccination. Likewise, the sub-optimal effectiveness of three doses of 720 EU in the rapidly accelerated schedule, if confirmed in future studies, might lead to a revision of the current schedule recommended for HIV-infected travellers.
Keywords:
AVC; Adult Vaccination Centre; Associated factors; HAART; HAV; HIV; Hepatitis A vaccination; IDD; IDU; Immune response; Infectious Diseases Department; MSM; Rapidly accelerated schedule; hepatitis A virus; highly-active antiretroviral therapy; injection drug users; men who have sex with men
Authors: Richard Gilson; Diarmuid Nugent; Kate Bennett; Caroline J Doré; Macey L Murray; Jade Meadows; Lewis J Haddow; Charles Lacey; Frank Sandmann; Mark Jit; Kate Soldan; Michelle Tetlow; Emilia Caverly; Mayura Nathan; Andrew J Copas Journal: Health Technol Assess Date: 2020-09 Impact factor: 4.014
Authors: Noele P Nelson; Mark K Weng; Megan G Hofmeister; Kelly L Moore; Mona Doshani; Saleem Kamili; Alaya Koneru; Penina Haber; Liesl Hagan; José R Romero; Sarah Schillie; Aaron M Harris Journal: MMWR Recomm Rep Date: 2020-07-03
Authors: Macey L Murray; Jade Meadows; Caroline J Doré; Andrew J Copas; Lewis J Haddow; Charles Lacey; Mark Jit; Kate Soldan; Kate Bennett; Michelle Tetlow; Mayura Nathan; Richard Gilson Journal: BMC Med Res Methodol Date: 2018-11-06 Impact factor: 4.615
Authors: Elvira Couto; Vicenç Diaz-Brito; Beatriz Mothe; Alberto C Guardo; Irene Fernandez; Ainoa Ugarte; Flor Etcheverry; Carmen E Gómez; Mariano Esteban; Judit Pich; Joan Albert Arnaiz; Juan Carlos López Bernaldo de Quirós; Christian Brander; Montserrat Plana; Felipe García; Lorna Leal Journal: Vaccines (Basel) Date: 2019-11-07
Authors: Aída de Fátima Thomé Barbosa Gouvêa; Maria Isabel de Moraes Pinto; Maristela Miyamoto; Daisy Maria Machado; Silvana Duarte Pessoa; Fabiana Bononi do Carmo; Suênia Cordeiro de Vasconcelos Beltrão; Regina Célia de Menezes Succi Journal: Rev Paul Pediatr Date: 2015-03-28